has placed a clinical hold on Novavax's (NVAX) Investigational New Drug (IND) application for its COVID-19-Influenza Combination (CIC) and stand-alone influenza vaccine candidates." Novavax specified ...
Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...
(Reuters) -Novavax cut its annual revenue forecast on Tuesday, citing lower-than-expected sales of its COVID-19 vaccine, ...
Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, ...
The U.S. Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its standalone flu vaccines, the company said on Monday.
Novavax has inked another settlement for a past COVID-19 vaccine supply deal. The Maryland biotech has agreed to pay $123.8 million to end a COVID vaccine supply pact with the UK Health Security ...
(RTTNews) - Novavax, Inc. (NVAX) Monday said the Food and Drug Administration or FDA has removed the clinical hold on its COVID-19-Influenza Combination (CIC) and stand-alone influenza vaccine ...
Novavax has received the green light from the US Food and Drug Administration (FDA) to resume clinical trials for its ...
Novavax shares dropped Tuesday morning after the company slashed its full-year outlook when it announced its third-quarter results.
Novavax: The Novavax was the fourth COVID vaccine to be administered in the U.S., after Johnson & Johnson, which is no longer available. The Novavax vaccine is the only non-mRNA updated COVID ...
Novavax will be working with the clinical trial investigators and other partners to resume trial activities as quickly as possible. Also Read: DeSantis Administration Cautions Against Pfizer, Moderna ...
Novavax (NVAX.O), opens new tab said on Tuesday that it has entered into a termination and settlement agreement with the UK Health Security Agency (UKHSA) related to its COVID-19 vaccine supply ...